Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT200 in RAS/BRAF wild-type metastatic colorectal cancer after standard chemotherapy failure
CTR20180034Phase 2Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sct200 in metastatic colon cancer (mCRC), sponsored by Sinocelltech Group Limited. Started Jan 2018; status: completed.
02
Drugs
sct200
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20180034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180034.